invIOs

Exciting news from the labs! Our lead small molecule program, #INV501, has demonstrated strong preclinical proof of concept with promising results against various solid tumor types. Today we're announcing some of our results for the first time: lnkd.in/dpRq6C_J 🧵 (1/5)

We are excited by INV501's potential and the prospects for eventual development in a patient-friendly format such as a pill or capsule. Much remains to be done, but preliminary testing in other solid tumor indications is already affirming this novel compound's potential. (5/5)

We presented some of these significant data via a poster session at the recent European Association for Cancer Research (EACR) congress in Turin. You can also find our #EACR2023 abstract in the conference's online database: lnkd.in/djhHSDUS (4/5)

Exciting news from the labs! Our lead small molecule program, #INV501, has demonstrated strong preclinical proof of concept with promising results against various solid tumor types. Today we're announcing some of our results for the first time: lnkd.in/dpRq6C_J 🧵 (1/5)

Read the full report here to discover more of the invIOs story: reportery.io/reports/invios… #invIOs #biotech #immunooncology #oncology #digitalcommunications #digitalreporting #diversity #researchbeatscancer #sciencealwayswins (4/4)

👩‍🏫 We showcased promising data at three major scientific congresses in Europe and the US, and presented at more than 20 events 👏  Our excellent team now numbers 38 people, of whom two thirds are female, including numerous senior management positions (3/4)

Mini-🧵 Ahead of our AGM, we published our first-ever digital update to showcase invIOs's progress since launching in 2022: reportery.io/reports/invios…  It’s been an exciting first phase in our mission to bring new treatment options to cancer patients. A few highlights 👇 (1/4)

A pleasure to join the great and the good of Austria's capital markets community at Palais Niederösterreich for the #WienerBörsePreis 2023. Many thanks to the @wiener_boerse team for a fantastic evening, and congratulations to all the winners! #capitalmarkets #biotech #IPO

🇺🇸 Just a few days to go to #ASCO23! Our CMSO Romana Gugenberger and Head of Clinical Development Sarah Bischof will be flying the flag for invIOs at the @ASCO Annual Meeting – get in touch if you'd like to meet up. #invIOs #immunooncology #clinicalresearch #researchbeatscancer

🇺🇸 Looking forward to #BIO2023 on June 5-8 – one of the events of the #biotech year. #StandUpForScience is a great line to highlight the true value of the #innovations that #biotechnology creates for patients worldwide. Get in touch for meetings during the event! #partnering

We were privileged to welcome Professor Christoph Zielinski @cczielinski, one of Europe's leading medical oncologists, for a guest lecture on ICIs, biomarkers and the current state of the art in treating multiple tumors. More in our latest blog post: linkedin.com/pulse/lessons-…

🇦🇹 Don't miss #AustrianLifeScienceDay next week for some fascinating discussions around the future of healthcare, the development of personalised medicine and the growth of Austria's #biotech sector. @lifesciencevie

#invIOs is working to develop novel cancer therapies that empower patients' immune systems to fight back against solid tumors including #HNSCC: linkedin.com/pulse/getting-… #headandneck #getchecked #immunooncology #cancerawareness #biotech #immunotherapies #headandneckcancer #APN401

Head and neck is the sixth most common cancer type worldwide, with more than 890,000 cases every year. The survival rate is more than 80% if the cancer is caught early, according to @hncalliance #headandneck #getchecked #immunooncology #cancerawareness #headandneckcancer

Aprils is Head and Neck Cancer Awareness month – an opportunity to look at the importance of early detection as well as the development of novel treatments for solid tumors #headandneck #headandneckcancer #cancerawareness #getchecked #biotech #immunooncology #immunotherapy

Six patients total were treated in a multicenter, open-label, phase 1b feasibility trial (NCT03087591) evaluating 2 increasing dose levels of APN401. #AACR23 Read more: ow.ly/R6NN50NPwFr

APN401, an autologous cell therapy that silences Casitas B-lineage lymphoma-b (Cbl-b) in peripheral mononuclear cells (PBMCs), induced stable disease (SD) in 2 patients with advanced, metastatic solid tumors. ow.ly/a59U50NPzIn

Looking forward to presenting the latest from our innovative #cancer #immunotherapy programs at #LSXWorld in #London. Our presentation is at 11:30 a.m. on 3 May during the Biotech Showcase Agenda. Get in touch for meetings during the event! #biotech #innovation #immunooncology